| Objective:To further confirm the therapeutic significance of Tongxinluo capsule in patients with coronary heart disease and its influence on the level of MMP-2 and MMP-9,so as to provide objective clinical basis for further promotion of Tongxinluo capsule in clinical practice.Methods : A total of 80 patients with coronary atherosclerotic heart disease admitted to the First Affiliated Hospital of Kunming Medical University from January2021 to December 2022 were selected as the research objects.The randomized control method was used to number the cases according to the order of treatment,and the random number table method was used to randomly divide the patients into the treatment group and the control group,with 40 cases in each group.Blood lipid(triglyceride,total cholesterol,low density lipoprotein),left ventricular end-diastolic inner diameter,left ventricular ejection fraction,serum MMP-2 and MMP-9 levels were examined in both control group and treatment group upon admission.Before taking Tongxinluo capsules,patients in both groups had taken aspirin enteric coated tablets(100mg QD),Clopidogrel sulfate tablets(75mg QD)and Rosuvastatin calcium tablets(10mg QD)for at least half a year,and were treated with β-blockers and ACEI or ARB drugs according to their own conditions.Compared with the control group,Tongxinluo capsule(Z19980015)was added to the treatment group on the basis of drug treatment,4 capsules at a time,3 times a day.Both groups took 60 days as a course of treatment,and were observed a course of treatment.At the end of the treatment cycle,the above indexes were going to be reviewed again.Serum MMP-2,MMP-9,triglyceride,total cholesterol,low density lipoprotein,left ventricular end-diastolic diameter and ejection fraction were going to be compared and analyzed between the two groups.Results:1.Comparison of clinical baseline data between the experimental group and the control group: there was no statistical difference between the two groups after statistical analysis of basic clinical data such as gender,age and weight on day 1(P >0.05).2.Comparison of MMP-2 and MMP-9 indexes between experimental group and control group: There was no statistical difference in the level of MMP-2 in the control group on day 1 and day 60(t=-0.149,P > 0.05),there was statistical difference in the level of MMP-2 in the treatment group on day 1 and day 60(t=4.021,P < 0.05),there was no statistical difference in the level of MMP-2 between the control group and the treatment group on day 1(t=0.806,P > 0.05),there were statistical differences in the level of MMP-2 between the control group and the treatment group on the 60 th day(P < 0.05).There was no statistical difference in the level of MMP-9 in the control group on day 1 and day 60(t=0.416,P > 0.05),there was statistical difference in the level of MMP-9 in the treatment group on day 1 and day 60(t=4.984,P < 0.05),there was no statistical difference in the level of MMP-9 between the control group and the treatment group on day 1(t=-0.243,P > 0.05),there were significant differences in the level of MMP-9 between the control group and the treatment group on day 60(t=4.803,P < 0.05).3.Comparison of triglyceride,total cholesterol,low density lipoprotein,left ventricular end-diastolic diameter and ejection fraction between experimental group and control group: There was no statistically significant difference in triglyceride level between the control group on day 1 and day 60(z=-0.894,P > 0.05),there was statistically significant difference in triglyceride level between the treatment group on day 1 and day 60(z=-3.152,P < 0.05),and there was no statistically significant difference in triglyceride level between the control group and the treatment group on day 1(z=-0.549,P > 0.05),there were statistically significant differences in triglyceride level between control group and treatment group on day 60(z=-2.040,P < 0.05).There was no statistical difference in total cholesterol level between the control group on day 1 and day 60(t=0.359,P > 0.05),there was statistical difference in total cholesterol level between the treatment group on day 1and day 60(t=3.050,P < 0.05),there was no statistical difference between the control group and the treatment group on day 1(t=-0.397,P > 0.05),the total cholesterol level of the control group and the treatment group at day 60 was statistically different(t=2.377,P < 0.05).There was no significant difference in the level of low density lipoprotein in the control group on day 1 and day 60(z=-1.654,P > 0.05),while there was significant difference in the level of low density lipoprotein in the treatment group on day 1 and day 60(z=-3.260,P < 0.05).There was no significant difference in the low density lipoprotein level between the control group and the treatment group on day 1(z=-0.221,P > 0.05),but there was significant difference in the low density lipoprotein level between the control group and the treatment group on day 60(z=-2.570,P < 0.05).There was no significant difference in the left ventricular end-diastolic diameter between day 1 and day 60 in the control group(t=1.978,P >0.05),while there was significant difference in the left ventricular end-diastolic diameter between day 1 and day 60 in the treatment group(t=5.781,P < 0.05).There was no significant difference in the left ventricular end-diastolic diameter between the control group and the treatment group on day 1(t=-0.575,P > 0.05),while there was a significant difference in the left ventricular end-diastolic diameter between the control group and the treatment group on day 60(t=4.101,P < 0.05).There was no statistically significant difference in ejection fraction between the control group on day 1 and day 60(z=-1.476,P > 0.05),there was statistically significant difference in ejection fraction between the treatment group on day 1 and day 60(z=-2.855,P <0.05),and there was no statistically significant difference between the control group and the treatment group on day 1(z=-0.501,P > 0.05),there were statistically significant differences in ejection fraction between control group and treatment group on day 60(z=-1.977,P < 0.05).conclusion:Tongxinluo capsule can decrease the patients with coronary heart disease(CHD)in serum level of MMP-2 and MMP-9 ， in on the basis of conventional western medicine treatment can improve ejection fraction,improve cardiac function,in order to delay the progress of ischemic cardiomyopathy,and is worth popularizing in clinical use. |
PDF Full Text Request